Dear Freddie
Investitore di Private Equity presso Monograph Capital Advisors (UK) LLP
Profilo
Freddie Dear is currently working as a Principal at Monograph Capital Advisors (UK) LLP since 2021.
He is also serving as the Vice President-Corporate Development at Ascend Gene & Cell Therapies Ltd.
since 2022.
Previously, Freddie worked as an Operations Director at Quell Therapeutics Ltd.
from 2019 to 2020.
He also held the position of Partner at Syncona Partners LLP from 2018 to 2021.
Freddie completed his undergraduate degree from The University of Edinburgh in 2016.
Posizioni attive di Dear Freddie
Società | Posizione | Inizio |
---|---|---|
Monograph Capital Advisors (UK) LLP
Monograph Capital Advisors (UK) LLP Investment ManagersFinance Monograph Capital Advisors (UK) LLP (Monograph Capital) is a private equity and venture capital firm founded in 2021 by Fred Ehrenkranz Cohen and Charles Conn. The firm is headquartered in London, GB. | Investitore di Private Equity | 01/12/2021 |
Ascend Gene & Cell Therapies Ltd.
Ascend Gene & Cell Therapies Ltd. Miscellaneous Commercial ServicesCommercial Services Ascend Gene & Cell Therapies Ltd. is a gene and cell therapy manufacturing specialist that aims to create effective gene therapies to a world-class standard. The company is based in Altrincham, UK, and has subsidiaries in Germany. The British company focuses on constantly refining and flexing their approach and embracing opportunities to innovate to create therapies that change lives. Ascend has over $130m of funding as expert teams merge. The company has a solid platform that allows their team to do their best work and deliver unwavering quality. Timothy Michael Funnell has been the CEO of the company since 2021. | Corporate Officer/Principal | 01/12/2021 |
Precedenti posizioni note di Dear Freddie
Società | Posizione | Fine |
---|---|---|
Syncona Partners LLP
Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | Investitore di Private Equity | 31/12/2021 |
Quell Therapeutics Ltd.
Quell Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Quell Therapeutics Ltd. is a London-based biotechnology company, which develops immune cell therapies to target transplant rejection, autoimmune and inflammatory diseases. It develops engineered T regulatory cell therapies for a variety of non-cancer targets. The company was founded on March 19, 2019 and is headquartered in London, the United Kingdom. | Direttore operativo | 31/03/2020 |
Formazione di Dear Freddie
The University of Edinburgh | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 4 |
---|---|
Syncona Partners LLP
Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | Finance |
Monograph Capital Advisors (UK) LLP
Monograph Capital Advisors (UK) LLP Investment ManagersFinance Monograph Capital Advisors (UK) LLP (Monograph Capital) is a private equity and venture capital firm founded in 2021 by Fred Ehrenkranz Cohen and Charles Conn. The firm is headquartered in London, GB. | Finance |
Ascend Gene & Cell Therapies Ltd.
Ascend Gene & Cell Therapies Ltd. Miscellaneous Commercial ServicesCommercial Services Ascend Gene & Cell Therapies Ltd. is a gene and cell therapy manufacturing specialist that aims to create effective gene therapies to a world-class standard. The company is based in Altrincham, UK, and has subsidiaries in Germany. The British company focuses on constantly refining and flexing their approach and embracing opportunities to innovate to create therapies that change lives. Ascend has over $130m of funding as expert teams merge. The company has a solid platform that allows their team to do their best work and deliver unwavering quality. Timothy Michael Funnell has been the CEO of the company since 2021. | Commercial Services |
Quell Therapeutics Ltd.
Quell Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Quell Therapeutics Ltd. is a London-based biotechnology company, which develops immune cell therapies to target transplant rejection, autoimmune and inflammatory diseases. It develops engineered T regulatory cell therapies for a variety of non-cancer targets. The company was founded on March 19, 2019 and is headquartered in London, the United Kingdom. | Health Technology |
- Borsa valori
- Insiders
- Dear Freddie